DiaMedica Therapeutics (NASDAQ:DMAC) Stock Moved Up to “Hold” by Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of DiaMedica Therapeutics (NASDAQ:DMAC – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Other research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Thursday, October 15th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, DiaMedica Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Check Out Our Latest Report on DiaMedica Therapeutics

DiaMedica Therapeutics Stock Performance

DiaMedica Therapeutics stock opened at $8.72 on Friday. The company has a 50-day simple moving average of $7.35 and a 200-day simple moving average of $6.77. The firm has a market capitalization of $470.27 million, a P/E ratio of -12.11 and a beta of 0.92. DiaMedica Therapeutics has a one year low of $5.24 and a one year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. As a group, sell-side analysts forecast that DiaMedica Therapeutics will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DMAC. AWM Investment Company Inc. acquired a new position in DiaMedica Therapeutics in the second quarter worth approximately $253,000. Bank of America Corp DE raised its position in DiaMedica Therapeutics by 62.5% during the first quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after acquiring an additional 16,446 shares in the last quarter. World Investment Advisors lifted its stake in DiaMedica Therapeutics by 7.7% in the fourth quarter. World Investment Advisors now owns 36,975 shares of the company’s stock valued at $294,000 after acquiring an additional 2,650 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in DiaMedica Therapeutics in the first quarter valued at approximately $356,000. Finally, Sei Investments Co. lifted its stake in DiaMedica Therapeutics by 100.0% in the first quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock valued at $754,000 after acquiring an additional 55,660 shares during the last quarter. Institutional investors and hedge funds own 10.12% of the company’s stock.

About DiaMedica Therapeutics

(Get Free Report)

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases affecting the kidneys and nervous system. The company’s research is centered on therapies intended to address conditions with limited treatment options.

DiaMedica’s lead investigational product is DM199, a recombinant form of human tissue kallikrein-1, an enzyme involved in blood flow regulation and vascular function. The company has evaluated DM199 in clinical development programs targeting acute ischemic stroke and kidney-related diseases, including chronic kidney disease.

Further Reading